Method Development and Validation for Quantitative Estimation of Bortezomib in its Bulk and Pharmaceutical Formulation
Abstract
A new method was established for estimation of Bortezomib by RP-HPLC method. The chromatographic conditions were successfully developed for the separation of Bortezomib by using Phenomenex Luna C18 column 250x4.6mm 5µm, flow rate was 1.0 ml/min, mobile phase ratio was Acetonitrile : 0.1% formic acid (50: 50 v/v),detection wavelength was 280 nm. The retention time was found to be 5.3 mins. The % purity of Bortezomib was found to be 100.443% respectively. The system suitability parameters for Bortezomib such as theoretical plates and tailing factor were found to be more than 2000 and less than 2 respectively, the resolution was found to be less than 2. The analytical method was validated according to ICH guidelines (ICH, Q2 (R1). The linearity study for Bortezomib was found in concentration range of 20µg-120µg/ml and correlation coefficient (r2) was found to be 0.9994, % recovery was found to be 101.37%, % RSD for repeatability was 1.778, % RSD for intermediate precision was 1.537 respectively. The precision study was precise, robust, and repeatable. LOD value was 2.6402, and LOQ value was 7.281 respectively. Hence the suggested RP-HPLC method can be used for routine analysis of Bortezomib in API and pharmaceutical dosage form.
Keywords: Analytical Validation, Bortezomib, Phamarmaceutical, formulation.
Keywords:
Analytical Validation, Bortezomib, Phamarmaceutical, formulationDOI
https://doi.org/10.22270/jddt.v13i6.5889References
Janet Beula S, Ramamohan Reddy T, Viswaja M, Ramulu Y, Stability Indicating RP-HPLC Method Development and Validation for The Simultaneous Estimation of Flupentixol and Melitracen in API from and Marketed Tablet Dosage form, Asian Journal of Pharmaceutical Analysis, 2022; 12(2):2-9. https://doi.org/10.52711/2231-5675.2022.00021
Jagadeswara Rao K, Mohan B, Venugopal NVS, Murali Mohan SV, Rama Rao M, A validated reverse phase stability-indicating HPLC method for bortezomib in the presence of degradation products and its process-related impurities, International Journal of Pharmaceutical Chemistry and Analysis, 2016; 3(3):150-161. https://doi.org/10.5958/2394-2797.2016.00021.6
Chandramowli B, Bigala BR, Development and validation of HPLC-UV method for the estimation of Bortezomib in human plasma, International Journal of Pharmacy and Analytical Research, 2017; 6(3):501-506.
Rambabu C, Estimation of bortezomib in bulk and its pharmaceutical dosage forms by Using a novel validated accurate reverse phase high performance liquid Chromatography, International Journal of Pharmacy and Pharmaceutical Sciences, 2011; 3(3):303-305.
Banothu Srikanth, Greg Maryann Nzubechuwku, Bello Munirat Omowumi, Jacintah David Kolo, & Zoya Fatima. RP-HPLC Method Development and Validation for the Simultaneous Estimation of Ivermectin and Albendazole in its Pure and Combine Dosage Form. Future Journal of Pharmaceuticals and Health Sciences, 2022; 2(3):170-184. https://doi.org/10.26452/fjphs.v2i3.280
Stephen R. Byrn, Patrick A. Tishmack, Mark J. Milton, Helgi van de Velde, Analysis of Two Commercially Available Bortezomib Products: Differences in Assay of Active Agent and Impurity Profile, AAPS Pharm Sci Tech, 2011; 12(2):461-467. https://doi.org/10.1208/s12249-010-9554-1
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. The New England Journal of Medicine, 2005; 352:2487-2498. https://doi.org/10.1056/NEJMoa043445
Venkataramana K, Sudhakar B, Anwar SKC, a validated stability-indicating uf lc method for bortezomib in the presence of degradation product and its process-related impurities, IJLSPR . 2012; 2(1):135-146.
Rambabu, C., Venkatrao, S., Ramu, G., Ganesh, M,. Estimation of bortezomib in bulk and its pharmaceutical dosage forms by using a novel validated accurate reverse phase high performance liquid chromatography. International Journal of Pharmacy and Pharmaceutical Sciences. 2011; 3:24-29.
Sudheer Kumar H M, & Kothapalli Bannoth Chandrasekhar. (2022). Stability Indicating Analytical Technique Development and Validation for the Determination of Fexinidazole in Bulk and Dosage Form Utilizing RP-HPLC. Future Journal of Pharmaceuticals and Health Sciences, 2022; 2(4):293-300. https://doi.org/10.26452/fjphs.v2i4.321
Clemens J, Longo M, Seckinger A, Hose D, Haefeli WE, Weiss J, Burhenne J, Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry, Journal of Chromatography. A, 2014; 1345:128-138. https://doi.org/10.1016/j.chroma.2014.04.024
Manapati Jyothi, Varaprasad A, Vandana B, Nikitha G, Sandhya S, & Sukanya U. RP-HPLC Method Designed for Determining Charantin in its Capsule Dosage Form. Future Journal of Pharmaceuticals and Health Sciences, 2021; 1(3):118-122. https://doi.org/10.26452/fjphs.v1i3.219
Teresa P, Scott Daniels J, Labutti J, Parsons I, Darrell N, Elizabeth B, Frank H, Liang-Shang G, Gerald M, Human metabolism of the proteasome inhibitor bortezomib:identification of circulating metabolites, Drug Metabolism and Disposition, 2006; 33(6):771-777. https://doi.org/10.1124/dmd.104.002956
Venkat R, Srinivasarao S, Ramu M, Rambabu GC, UV Visible spectrophotometric determination of bortezomib in its bulk and formulation dosage forms, Der Pharmacia Lettre, 2012; 4(3):720-727. http://scholarsresearchlibrary.com/archive.html
Banothu Srikanth, Aaysha Firdose, Muna, & Mubarak Ibrahim Ahmed Mohamed. (2021). Analytical Validation and Simultaneous Estimation of Cefixime and Ornidazole by RP-HPLC Method. International Journal of Clinical Pharmacokinetics and Medical Sciences, 2021; 1(2):42-48. https://doi.org/10.26452/ijcpms.v1i2.196
Published
Abstract Display: 550 
PDF Downloads: 474 PDF Downloads: 242 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.